Purchase Zopiclone (Imovane) sleeping pills online


How and where to order Imovane (Zopiclone) 7.5 mg, 10 mg tablets online:

Shop 1: MEDS DIRECT SHOP - 30% bonus pills for all reorders
Shop 2: MEDSTORE ONLINE - 5% discount coupon 5off_2021
Prices: from $1.46 per pill
Forms: Zopiclone 7.5 mg tablets, Zopisign 10 mg tablets
Quantity: 30, 60, 90, 120, 180 pills
Type: Zopiclone brand, Zopisign brand, Imovane generic
Payment: Visa, Mastercard, AmEx, Cryptocurrency
Delivery: Registered airmail, international delivery service
Shipping: USA, UK, Europe, Canada, Australia

Indications and usage:

Zopiclone (Imovane) is indicated for the short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings.

Treatment with zopiclone sleeping pills should usually not exceed 7-10 consecutive days. Use for more than 2-3 consecutive weeks requires complete re-evaluation of the patient. Prescriptions for zopiclone should be written for short-term use (7-10 days) and it should not be prescribed in quantities exceeding a 1-month supply.

The use of hypnotics should be restricted for insomnia where disturbed sleep results in impaired daytime functioning.


Dosage and administration:

  • Imovane should only be taken when you are able to get a full night's sleep (7 to 8 hours) before you need to be active again.
  • The standard adult dose of zopiclone is one tablet just before you go to bed.
  • This medication should be taken in a single intake and not readministered during the same night.
  • If you are over 65 years of age the dose is half a tablet taken just before you go to bed.
  • If you have a liver or kidney problem, the usual recommended dose is half a tablet taken just before you go to bed.


    Dosage forms and strengths:

    Imovane (Zopiclone) tablets 7.5 mg.


    Overdosage:

    Signs and symptoms:

    Overdose by zopiclone pills is usually manifested by varying degrees of central nervous system depression ranging from drowsiness to coma according to the quantity ingested. In mild cases, symptoms include drowsiness, confusion, and lethargy; in more severe cases, symptoms may include ataxia, hypotonia, hypotension, methaemoglobinaemia, respiratory depression, and coma. Overdose should not be life threatening unless combined with other CNS depressants, including alcohol. Other risk factors, such as the presence of concomitant illness and the debilitated state of the patient, may contribute to the severity of symptoms and very rarely can result in fatal outcome.

    In voluntary or accidental cases of zopiclone overdosage involving doses up to 340 mg, the principal effects reported were prolonged sleep, drowsiness, lethargy and ataxia.

    Recommended treatment:

    Symptomatic and supportive treatment in adequate clinical environment is recommended, attention should be paid to respiratory and cardiovascular functions. Gastric lavage or activated charcoal is only useful when performed soon after ingestion.

    Hemodialysis is of no value due to the large volume of distribution of zopiclone. Flumazenil may be a useful antidote; however, flumazenil administration may contribute to the appearance of neurological symptoms (agitation, anxiety, convulsionsand emotional lability). Intravenous fluids should be administered as needed.


    Contraindications:

    Imovane (Zopiclone) is contraindicated in patients with:

  • known hypersensitivity to the drug or to any component inits formulation
  • myasthenia gravis
  • severe hepatic insufficiency
  • severe impairment of respiratory function (e.g., significant sleep apnea syndrome)


    Warnings and precautions:

    Avoid to take Zopiclone (Imovane) tablets if you have:

  • been drinking alcohol or you believe that you may have alcohol in your bloodstream
  • sleep apnoea (a condition where you temporarily stop breathing while you sleep)
  • myasthenia gravis (a condition in which the muscles become weak and tire easily)
  • severe liver problems
  • acute and/or severe lung problems
  • had a stroke
  • as a long term treatment
  • ever experienced sleep-walking or other unusual behaviour (suchas driving, eating, making a phone call or having sex etc.) while not being fully awake after taking zopiclone


    Adverse reactions, side effects:

    Most common zopiclone adverse reactions: headaches, dry mouth, bitter taste in your mouth, drowsiness.

    Less common side effects include: heartburn, nausea, vomiting and/or diarrhoea, change in appetite, stomach pain, rash, agitation, depression, confusion, anxiety, dizziness, blurred vision, impotence, sleep walking or other unusual behaviours (such as driving, eating, making a phone call, or having sex etc.) while not being fully awake.

    To report suspected adverse reactions of Imovane (Zopiclone) tablets, contact Sanofi pharmaceutical company or your local FDA.


    Drug interactions:

    The risk of zopiclone drug interaction arising from displacement of bound drug is low.

    Be careful wneh you use this medication with:

  • alcohol
  • CNS depressants
  • drugs affecting cytochrome P450 enzymes
  • opioids


    Use in specific populations:

    Elderly (65 years of age or more), debilitated patients and/or patients with liver, kidney, or chronic respiratory problems should start with 3.75 mg (one-half of a 7.5 mg tablet) at bedtime just before retiring. The dose in elderly, debilitated patients and/or patients with liver or kidney problems is not to exceed 5 mg.


    Drug abuse and dependence:

    Use of sedative/hypnotics agents like zopiclone may lead to the development of physical and psychological dependence or abuse. The risk of dependence or abuse is increased with the dose and duration of treatment, if used with alcohol or other psychotropics, in patients with a history of alcoholism and/or drug abuse or in patients with marked personality disorders. Interdose daytime anxiety and rebound anxiety may increase the risk of dependency in zopiclone treated patients.


  • Preclinical Testing Solutions
    Throughout the
    Product Innovation Cycle.